Rheumatology Medical News about Arthritis, Rheumatoid Medication Therapy Management Drug Costs

Your Unread Messages

See All

Tracy Hampton, PhD

FDA Update

Anti-CD20 Antibody Granted Accelerated Approval for CLL

Roberta Buell, MBA
Congress Proposes SGR Fix

Dorothy J. Schirf, MD

Technology Advances

Radiosurgery Trial Sparks Optimism for Early Lung Cancer

Sara Hartley

Cancer Science

Using Embryonic Stem Cells to Test Breast Cancer Genes

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents. A Cost-Effectiveness Analysis
Annals of Internal Medicine, 11/03/09

Finckh A et al. – The investigators used available data to estimate the cost–effectiveness of initial treatment strategies for RA. Compared with stepped care, early DMARDs or early biologic agents seem to improve outcomes, but only DMARDs do so at a cost per year of life saved that society typically considers acceptable.

<< Previous
Role of the pituitary-bone axis in skeletal pathophysiology

Next >>
Bone Microstructure at the Distal Tibia Provides a Strength...